Table 1 Summary of the included studies in the meta-analysis
Author | Year | Duration (wk) | Drug before | Background regimen | Group 1 (n) | Group 2 (n) | Group 3 (n) | Group 4 (n) | Group 5 (n) | Group 6 (n) |
|---|---|---|---|---|---|---|---|---|---|---|
Rosenstock J et al S1 [28] | 2012 | 12 | Metformin | Metformin | PBO (65) | CANA 50 mg QD (64) | CANA 100 mg QD (64) | CANA 200 mg QD (65) | CANA 300 mg QD (64) | CANA 300 mg BID (64) |
Yale JF et al [29] | 2013 | 26 | N/R | N/R | PBO (90) | CANA 100 mg QD (90) | CANA 300 mg QD (89) | Â | Â | Â |
Stenlof K et al [16] | 2013 | 26 | Diet and exercise | - | PBO (192) | CANA 100 mg QD (195) | CANA 300 mg QD (197) | Â | Â | Â |
Ferrannini E et al S1 [32] | 2013 | 12 | Â | Â | PBO (82) | EMPA 5 mg QD (81) | EMPA 10 mg QD (81) | EMPA 25 mg QD (82) | Â | Â |
Fonseca VA et al [31] | 2012 | 12 | N/R | - | PBO (69) | IPRA 12.5 mg QD (70) | IPRA 50 mg QD (67) | IPRA150 mg QD (68) | IPRA 300 mg QD (68) | Â |
Wilding JPH et al S1 [30] | 2013 | 12 | Metformin | - | PBO (66) | IPRA 12.5 mg QD (69) | IPRA 50 mg QD (68) | IPRA 150 mg QD (67) | IPRA 300 mg QD (72) | Â |
Wilding JPH et al S2 [18] | 2009 | 12 | Â | Insulin | PBO (19) | DAPA 10 mg QD (23) | DAPA 20 mg QD (23) | Â | Â | Â |
Bailey CJ et al S1 [19] | 2012 | 24 | Naïve | - | PBO (68) | DAPA 1 mg QD (72) | DAPA 2.5 mg QD (72) | DAPA 5.0 mg QD (66) |  |  |
Ferrannini E et al S2 [20] | 2010 | 24 | Naïve | - | PBO (75) | DAPA 2.5 mg QD (65) | DAPA 5.0 mg QD (64) | DAPA 10 mg QD (70) |  |  |
Henry RR et al [21] | 2012 | 24 | Naïve | Metformin | PBO 1 (201) | DAPA 5 mg QD (194) | DAPA 10 mg QD (211) | PBO 2 (208) |  |  |
Strojek K et al [22] | 2011 | 24 | Glimepiride | Glimepiride | PBO (145) | DAPA 2.5 mg QD (154) | DAPA 5 mg QD (142) | DAPA 10 mg QD (151) | Â | Â |
Bailey CJ et al S2 [23] | 2010 | 24 | Metformin | - | PBO (137) | DAPA 2·5 mg QD (137) | DAPA 5 mg QD (137) | DAPA 10 mg QD (135) |  |  |
Bolinder J et al [24] | 2012 | 24 | N/R | Metformin | PBO (91) | DAPA 10 mg QD (88) | Â | Â | Â | Â |
Rosenstock J et al S2 [25] | 2012 | 24 | Pioglitazone | Pioglitazone | PBO (139) | DAPA 5 mg QD (141) | DAPA 10 mg QD (140) | Â | Â | Â |
Kaku K et al [5] | 2013 | 12 | Naïve | - | PBO (54) | DAPA 1 mg QD (59) | DAPA 2.5 mg QD (56) | DAPA 5 mg QD (58) | DAPA 10 mg QD (52) |  |
Wilding JPH et al S3 [26] | 2012 | 24 | Insulin | Insulin | PBO (166) | DAPA 2.5 mg QD (179) | DAPA 5 mg QD (185) | DAPA 10 mg QD (173) | Â | Â |
List JF et al [27] | 2009 | 12 | Naïve | - | PBO (54) | DAPA 2.5 mg QD (59) | DAPA 5 mg QD (58) | DAPA 10 mg QD (47) | DAPA 20 mg QD (59) | DAPA 50 mg QD (56) |